Literature DB >> 4043203

Transfer of labetalol into amniotic fluid and breast milk in lactating women.

N O Lunell, J Kulas, A Rane.   

Abstract

The transfer of labetalol into human breast milk and amniotic fluid was studied in women with pregnancy hypertension. The women were treated with labetalol 600-1200 mg daily. The ratio between the areas under the milk and plasma concentration versus time curves varied between 0.8 and 2.6. No consistent relation between milk and plasma concentration in the mother was observed either within the individuals during a dose interval or between different individuals. One of the nursed infants at the end of the dose interval had a plasma labetalol in the same range as the mother, and in another infant the level was below the detection limit. Amniotic fluid concentrations 2-3 h after dosing were generally lower than in plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043203     DOI: 10.1007/bf00544073

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Some further evidence for partial agonist activity of labetalol.

Authors:  A J Riley
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

2.  Excretion of oxprenolol and timolol in breast milk.

Authors:  J Fidler; V Smith; M De Swiet
Journal:  Br J Obstet Gynaecol       Date:  1983-10

Review 3.  Clinical pharmacology of labetalol.

Authors:  D A Richards; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Metoprolol excretion into breast milk.

Authors:  B Sandström; C G Regårdh
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Transplacental passage of atenolol in man.

Authors:  A Melander; B Niklasson; I Ingemarsson; H Liedholm; B Scherstén; N O Sjöberg
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

7.  The evaluation of labetalol in the treatment of hypertension complicating pregnancy.

Authors:  C A Michael
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Atenolol and metoprolol. A comparison of their excretion into human breast milk.

Authors:  J Kulas; N O Lunell; U Rosing; B Stéen; A Rane
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1984

9.  Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.

Authors:  N O Lunell; P Hjemdahl; B B Fredholm; H Nisell; B Persson; J Wager
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

10.  Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients.

Authors:  G Koch
Journal:  Am Heart J       Date:  1977-05       Impact factor: 4.749

  10 in total
  8 in total

Review 1.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 2.  Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.

Authors:  Gail D Anderson; Darcy B Carr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination.

Authors:  H Jeong; S Choi; J W Song; H Chen; J H Fischer
Journal:  Xenobiotica       Date:  2008-01       Impact factor: 1.908

4.  Use of common migraine treatments in breast-feeding women: a summary of recommendations.

Authors:  Susan Hutchinson; Michael J Marmura; Anne Calhoun; Sylvia Lucas; Stephen Silberstein; B Lee Peterlin
Journal:  Headache       Date:  2013-03-06       Impact factor: 5.887

Review 5.  Hypertension in pregnancy: natural history and treatment options.

Authors:  L Foo; J Tay; C C Lees; C M McEniery; I B Wilkinson
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

Review 6.  The Risk for Neonatal Hypoglycemia and Bradycardia after Beta-Blocker Use during Pregnancy or Lactation: A Systematic Review and Meta-Analysis.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Viraraghavan V Ramaswamy; Sinno H P Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  Int J Environ Res Public Health       Date:  2022-08-04       Impact factor: 4.614

Review 7.  Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.

Authors:  Dylan van de Vusse; Paola Mian; Sam Schoenmakers; Robert B Flint; Willy Visser; Karel Allegaert; Jorie Versmissen
Journal:  Eur J Clin Pharmacol       Date:  2022-09-15       Impact factor: 3.064

8.  Risk for neonatal hypoglycaemia and bradycardia after beta-blocker use during pregnancy or lactation: a systematic review and meta-analysis protocol.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Sinno Hp Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  BMJ Open       Date:  2022-08-25       Impact factor: 3.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.